Cancer Research Institute Announces Second Investment from Its Cancer Vaccine Acceleration Fund to Enable Manufacture of Powerful Immune Stimulant
Cancer Research InstituteCancer Research Institute, a nonprofit organization, has awarded $450,000 to Oncovir, Inc., to Produce and Supply Hiltonol® (Poly-ICLC) for Use in Clinical Trials of Cancer Vaccines and Other Immunotherapies.